701 ‘Tomudex’ (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): First results of a phase III study
- 30 November 1995
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 31, S146
- https://doi.org/10.1016/0959-8049(95)95951-2
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: